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THE VIRTUAL PHYSIOLOGICAL HUMAN: TEN YEARS AFTER 
ABSTRACT 
Biomedical research and clinical practice are struggling to cope with the growing complexity 
that the progress of healthcare involves.  The most challenging diseases, those with the largest 40 
socioeconomic impact (cardiovascular conditions, musculoskeletal conditions, cancer, 
metabolic, immunity and neurodegenerative conditions) are all characterised by a complex 
genotype/phenotype interaction, and in general by a “systemic” nature that the traditional 
reductionist approach struggle to cope with.   In May 2005 a small group of researchers with 
different backgrounds met in Barcelona to discuss how the vision of computational 45 
physiology promoted by the Physiome Project could be translated into the clinical practice.  
In that meeting the term Virtual Physiological Human was formally proposed. We know a lot 
about these diseases, but our knowledge is fragmentary as it is associated with molecular and 
cellular processes on the one hand, and with tissue and organ phenotype changes (related to 
clinical symptoms of disease conditions) on the other. The problem could be solved if we 50 
could capture all these fragments of knowledge into predictive models and then compose 
them into hypermodels that help us to tame the complexity that such systemic behaviour 
involves.  In 2005 this was simply not possible - the necessary methods and technologies 
were not available.  Now, ten years later, it seems the right time to reflect on the original 
vision, the results achieved so far, and what remains to be done.  55 
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1. FROM THE PHYSIOME TO THE VPH 
Physiology has a long tradition, dating particularly from Claude Bernard in the 19th century, 
of quantitative research on the structure-function relationships that underpin physiological 
processes and the practice of medicine (1). This was a tradition that emphasized the 80 
integration of multidisciplinary knowledge using physical laws and mathematics, albeit at a 
simple level, to understand the complex processes of life. With the elucidation of the genetic 
and molecular basis of life, however, biomedical research in the latter half of the 20th century 
largely moved away from physiology and towards molecular biology.  
One outcome of 50 years of research in molecular biology is a comprehensive ‘parts list’ of 85 
proteins, with their associated genetic blueprints and their interactions with other proteins, 
fats and carbohydrates. We have a wonderful compendium of metabolic networks, signalling 
and gene regulatory pathways, membrane receptors, transporters, ion channels, and many 
more. Biomedical scientists have easy access to vast databases of structural and biophysical 
information at the molecular level, greatly assisted by the development of bioinformatics web 90 
user interfaces and search tools. These reductionist discoveries, that include the human 
genome, metabolome, much of the proteome, and now parts of the exome and microbiome, 
are one of the great achievements of late 20th and early 21st century science, but they have 
had little impact on public health or the practice of medicine because they are not integrated 
into physiology which, together with anatomy, is one of the two disciplines that underpin 95 
medical science. Physiology as a discipline has lacked either the means or the inclination to 
deal with the increasingly complex links between molecular biology and integrative 
physiological processes at the tissue level. 
Physiology should be providing the synthesis to match the reductionist analysis of molecular 
biology by integrating all the molecular information into an understanding of physiological 100 
function (‘putting humpty-dumpty together again’ (2)). Physiology has of course also made 
much progress in understanding whole body mechanisms over the past 50 years but it has had 
a tiny fraction of the funding in comparison with molecular biology, and the consequence is 
that we do not have anywhere near the same level of data and tools for synthesis. The other 
major issue is that the only way to quantitatively describe complex function is via 105 
mathematical models. Phenotype depends on models in the same way that genotype depends 
on a statement of nucleotide sequence.     
Somewhat ironically, in the physical sciences and engineering the second half of the 20th 
century was characterized by the growth of computational science – taking advantage of the 
doubling of compute power per unit cost every 18 months (Moore’s law (3)) and the ability of 110 
numerical techniques, such as the finite element method, to cope with complex physical and 
engineering challenges, such as aircraft design and space flight, by solving the well-known 
laws of physics that had largely been elucidated in the 19th century (e.g. mechanics, such as 
elasticity theory and the Navier-Stokes equations of fluid flow, thermodynamics, and 
Maxwell’s electromagnetic equations that now underpin all of electrical engineering and 115 
communications). Again ironically, physics and engineering have been crucial to progress in 
the development of instrumentation that has enabled much of the progress in molecular 
biology (e.g. sequencing machines, PCR, mass spectrometers) and the clinical imaging that 
has transformed clinical medicine (e.g. MRI, CT, PET and ultrasound). The divergence 
between the physical and biological sciences in the use of mathematics and computational 120 
tools for scientific understanding has possibly been exacerbated by education systems that 
often force students to choose between the ‘hard’ disciplines of physics and engineering and 
the ‘soft’ disciplines of biology and medicine.  
The International Union of Physiological Sciences (IUPS) recognized this problem in 1993 
and established the Physiome Project to bring engineering approaches and technologies into 125 
physiology. The concept of a “Physiome Project” was presented in a report from the 
Commission on Bioengineering in Physiology to the International Union of Physiological 
Sciences (IUPS) Council at the 32nd World Congress in Glasgow in 1993. The name comes 
from "physio-" (life) and "-ome" (as a whole), and is intended to provide a "quantitative 
description of physiological dynamics and functional behaviour of the intact organism" (4-7). 130 
 
2. THE VISION 
During the sixth framework program (FP6, 2002-2006) the EC had funded some research and 
technological projects where computational physiology, biophysics, and biomechanics 
methods had been used to address clinically relevant problem.  But in spite of the available 135 
expertise, there was a sense that Europe was missing the bus: the International Union of 
Physiological Societies had formally endorsed the IUPS Physiome Project in 1993, but the 
drive was primarily in New Zealand, in Japan, and in USA. Also, in April 2003, the 
Interagency Modeling and Analysis Group (IMAG) was formed, which coordinated program 
staff from the National Institutes of Health (NIH) and the National Science Foundation (NSF) 140 
who managed projects in this growing area. On the 1st of June 2005 a small group of 
researchers and officers from the European Commission (EC) met in an expert workshop in 
Barcelona.  Out of this meeting a White Paper was published in November 20051, where for 
the first time the term “Virtual Physiological Human” or VPH was used. 
Reading this document it is possible to identify three distinct themes, at that time barely 145 
integrated.  The first, inherited from the Physiome Project, was the use of computational 
physiology in the fundamental understanding of physiology and its dysfunction (disease), 
where systemic interactions hard to capture with traditional reductionist approaches were 
relevant.  In some of the early narratives (4) the Physiome Project was heavily inspired by the 
Human Genome Project, which started in 1990 and was completed in 2003.  Similar to the 150 
Genome Project, the challenge was presented as the collaborative development of a digital 
representation of the human body and its relevant physiological systems (i.e. the 
neuromusculoskeletal system), or organs (i.e. the heart). Because of the heterogeneity of the 
information to be shared this also posed a grand challenge in the area of data sharing and data 
modelling infrastructure.  The other element that permeated some early reports was the 155 
implicit idea of building a generic Human Physiome, which could eventually become a 
Reference Human Physiome, much like the effort of the Genome Reference Consortium2.  
The second theme was a pull towards clinical applications, in relation to the need for more 
individualised medical decisions, but also in the role that in silico methods could play in the 
development of new medical products.  Here the vision was more toward the development of 160 
patient-specific and problem-specific models, which could be used as decision-support 
systems in the clinical practice, for diagnosis, prognosis, or treatment planning.  
The third theme, less evident in the white paper, was a criticism of the overwhelming 
importance that had been given to single cell molecular biology in the past 20 years, both in 
terms of funding and the narrative within biomedical research.  The complete mapping of the 165 
human genome had been announced only two years before, and the over-hyped public 
discourse of genetics as the all-solving approach to medical research was at its zenith. A 
                                                
1 http://www.vph-institute.org/upload/file517569145f61b.pdf  
2 http://www.ncbi.nlm.nih.gov/projects/genome/assembly/grc/  
seminal popular science book “The Music of Life: Biology beyond genes” (8) elaborated with 
convincing evidence the argument for a more holistic approach. But to make real the 
integrative biology vision that Denis Noble advocated there was the need for a whole new 170 
“framework of methods and technologies that, once established, will allow the investigation 
of the human body as a whole” (9). 
In 2007 the STEP Consortium published “Seeding the EuroPhysiome: A Roadmap to the 
Virtual Physiological Human” (9).  The STEP support action, funded by the EC at the end of 
FP6, produced a roadmap that was the result of a large consensus process involving 318 175 
named experts worldwide.  All three themes mentioned above were still present, but now the 
narrative centred primarily on the second.  It was acknowledged that the phenotypical 
variability among subjects, especially if affected by a pathology, was so large that the 
usefulness of a reference physiome would have been quite limited; in addition it was 
acknowledged that “Models are usually developed for a very specific purpose” (see (9), 180 
section 3.2.2).  This is an important passage in the VPH vision: from 2007 the VPH became 
primarily a bioengineering effort, aimed at developing integrative patient-specific models 
targeting a well-defined predictive purpose of clinical relevance, which would typically be 
used as a decision support system.  The development of repositories of data and models was 
seen more as a necessary tool for the VPH practitioners than an endpoint in itself; also the 185 
more fundamental reflection of the epistemological role of integrative modelling in 
biomedical research was framed toward the need to develop credibility for predictive 
medicine technologies.  This focus became quite characteristic of the VPH in Europe. On the 
other hand, the 2007 2nd MEI International Symposium organised in Osaka by the Japanese 
Global Centre of Excellence on in silico medicine (10), and the 2009 IMAG Futures Meeting 190 
held on in Bethesda –Maryland3, presented a use of multiscale modelling much more oriented 
towards the understanding of fundamental physiology and pathology mechanisms, rather than 
clinical applications. 
In 2008 PriceWaterhouseCooper published a seminal report entitled “Pharma 2020: Virtual 
R&D - Which path will you take?” 4  where a second role was suggested for in silico 195 
technologies: the creation of Virtual Patients, computer simulations that could be used to infer 
the efficacy and safety of new biomedical products as they interacted with each patient’s 
anatomy, physiology, and life style.  This was a different target for the VPH, where patient-
specific models of real or synthetic patients could be used to test drugs or medical devices.  
Along a similar line is the 2009 report “Virtual Tissues: a quantum leap in biomedical 200 
research”5, co-authored by the US Environmental Protection agency. 
In 2009 the update of the VPH Research Roadmap elaborated by the VPH Network of 
Excellence (11), called for the creation of a “international non-profit organisation, whose 
mission is to ensure that the Virtual Physiological Human is fully realised, universally 
adopted, and effectively used both in research and clinic”.  Soon after the Virtual 205 
Physiological Human Institute for Integrative Biomedical Research (VPH Institute for short) 
was established6, as a virtual organisation to providing strategic leadership, initially in Europe 
but now globally, for the VPH/Physiome Project. 
                                                
3 http://www.vph-institute.org/upload/imag-futures-report_519244d3a0aa0.pdf  
4 http://www.vph-institute.org/upload/pwc-pharma2020-virtualrd-final_519245021a53a.pdf  
5 http://www.vph-institute.org/upload/v-tissue-position-paper-2009_555460b051aaa.pdf  
6 http://www.vph-institute.org  
In 2011 the vision of the VPH came to its full expression.  In a position paper on the 
forthcoming Horizon 2020 framework program7, the VPH Institute identified the scope of the 210 
VPH around three macroscopic targets: 
- Digital Patient: The VPH for the doctor; patient-specific modelling to support medical 
decisions. 
- In silico Clinical Trials: The VPH for the biomedical industry; collections of patient-
specific models to augment the pre-clinical and clinical assessment of new biomedical 215 
products.  In silico technologies for the reduction, refinement and partial replacement of 
animal and human experimentation. 
- Personal Health Forecasting: The VPH for the patient/citizen; subject-specific real-time 
simulations, based on data collected by wearable and environmental sensors, that provide 
advice to individuals affected by conditions requiring careful self-management, or to 220 
people simply at risk of developing certain diseases. 
In addition to these three targets, two horizontal themes were also identified: (i) that of the 
infrastructure for biomedical data generation, collection, processing, modelling, and sharing, 
(acknowledged as a technological, socioeconomic, regulatory, and ethical challenge); and (ii) 
that of the methodological, epistemological, and social challenges related to the assessment 225 
and the acceptance of predictive technologies.  
An in-depth analysis of the research vision for these five areas is beyond the scope of this 
review.  The interested reader should refer to the Discipulus Roadmap for the Digital Patient 
area8, and the Avicenna Roadmap for the in silico clinical trials area9.  Some aspects of data 
sharing and of modelling based on mobile health technologies are discussed in the recent 230 
paper entitled “Big Data, Big Knowledge: Big Data for Personalized Healthcare” (12). 
 
3. THE METHODS 
The goals of the Physiome Project in 1997 were: (i) to link tissue/organ level physiological 
function to mechanisms at the molecular scale, (ii) to develop model and data encoding and 235 
exchange standards for multiscale modelling to ensure model reproducibility and sharing, (iii) 
to develop modular approaches to ensure that self-contained models could be developed and 
validated independently before being incorporated into a hierarchy of imported models, and 
(iv) to develop free web-accessible model repositories and open source software based on the 
Physiome modelling and data standards. The dual focus of the VPH project when it started in 240 
2007 was to complement the physiological multiscale modelling focus of the Physiome 
Project with greater clinical relevance and industry opportunity.   
 
Modelling standards 
The first modelling standard developed by the Physiome Project was CellML10 (13; 14). This 245 
standard covers models that use ordinary differential equations and algebraic expressions 
(both of which can be nonlinear). The ‘ML’ refers to ‘Markup Language’ and in particular the 
                                                
7 http://www.vph-institute.org/upload/vphinst-position-on-fp8-greenpaper-v3_5192443874603.pdf  
8 http://www.vph-institute.org/upload/discipulus-digital-patient-research-roadmap_5270f44c03856.pdf  
9 http://avicenna-isct.org/roadmap/  
10 CellML began as a joint public-private initiative in 1998 with funding by the US company Physiome Sciences 
(CEO Jeremy Levin), before being launched under IUPS as a fully open source project in 1999. 
‘eXtensible Markup Language’ or XML, which is the Web2.0 standard11 for exchanging 
information on the web. CellML treats model syntax (the mathematics, which is encoded in 
MathML 12 ) separately from semantics (the biological and biophysical meaning of the 250 
mathematical terms, which is described via ontologies and encoded with RDF 13 ). The 
structure of a CellML model, including the use of imports to maintain modularity, is 
illustrated in Figure 1.  
 
Figure 1. Overall structure of the Noble62 CellML model showing the encapsulation hierarchy (purple), the 255 
CellML model imports (blue), and the other key parts (units, components & mappings) of the top level CellML 
model. Note that all units are defined in a units file and imported where needed (shown by the red arrows). Also 
the ion concentration parameters are defined in a parameters file and imported into the top-level file but passed 
down to the modules that use them via the mappings. 
In this example, the 1962 Noble model (15) of a cardiac action potential is built up from three 260 
separately defined sub-models (one for the sodium channel, one for the potassium channel, 
and one for the leakage channel). Note also that the units and the parameters for the model are 
also imported from separate files. Other features include components (for example the two 
types of sodium channel gate, the m-gate and the h-gate, are defined as separate components 
with the sodium channel model), mappings between components (this allows the visibility of 265 
parameters and variables to be controlled), grouping and encapsulation (to logically 
encapsulate a group of separate objects – say the three ion channels – into a single entity).  
                                                
11 The World Wide Web Consortium (http://w3c.org) is the governing body for Web standards and protocols. 
Web2.0 refers to a group of technologies, including XML, RDF and MathML, that emphasize user-generated 
content, usability, and interoperability.  
12 https://en.wikipedia.org/wiki/MathML  
13 https://en.wikipedia.org/wiki/Resource_Description_Framework  
CellML is designed to be very general in order to handle any type of biophysical model14 and, 
in order to support model imports, is a declarative language (unlike say C, Fortran or Matlab, 
which are procedural languages) so that the order of statements does not affect the solution. 270 
An Application Programming Interface (API) is available but more user-friendly software 
called OpenCOR15, developed to create, edit and run CellML models is also available (16). A 
related XML standard, designed specifically for biochemical reactions and developed by the 
systems biology community, called SBML16, has many alternative software platforms.   
A repository of CellML models has been developed17 that covers most areas of biology. There 275 
are about 600 model exposures (corresponding to 600 publications and available for public 
download) based on peer-reviewed publications, and another 400 workspaces (collaborative 
development environments that are password protected). Once a model has been published 
the workspace can generate an exposure for public access. Nearly all models are curated 
(checked to ensure that they have consistent units, they work and they give results consistent 280 
with the reference publication) and many are annotated (the terms in the model are linked 
through metadata to ontologies that provide biological and biophysical meaning). The 
mathematical equations for the model can be displayed directly on the website or in 
OpenCOR, and the model equations can be output in a variety of computer languages (C, 
C++, Fortran, Matlab, Python)18. This repository, which includes FieldML models as well as 285 
CellML models, is called the Physiome Model Repository (PMR)19. 
Another modelling standard developed under the VPH/Physiome Project, dealing with 
spatially varying structure and processes, is called FieldML. The term ‘Field’ refers to the 
concept, widely used in the physical sciences and engineering, of a spatially continuous field 
such as temperature or the oxygen concentration in a tissue being captured in a parametric 290 
model. The most common format for these models uses finite element basis functions that 
interpolate nodal parameters that are themselves the value of the field (and sometimes its 
spatial derivatives) at that material point. The whole field is made up of many such finite 
element patches, chosen with the spatial resolution needed to achieve any desired level of 
accuracy for either fitting measured data or representing the field solution of partial 295 
differential equations that characterize the physical processes being modelled.  A model 
repository and open source tools based on the FieldML standard are also available (17; 18).  
CellML and FieldML together provide the means to encode any biophysical model in a 
standardized and reproducible format. Data encoding standards are less well defined, although 
DICOM20 is a well-established standard for clinical images and BioSignalML21 is a standard 300 
developed by the VPH-Physiome community for time varying signal data. OpenCOR 
incorporates the BioSignalML API in order to import or export signal data in this format.      
 
                                                
14 https://www.cellml.org/   
15 http://opencor.ws. This is open source and freely available.    
16 http://sbml.org  
17 https://models.physiomeproject.org/cellml   
18 http://www.cellml.org/about/publications has an extensive list of publications on CellML and OpenCOR. 
19 https://models.physiomeproject.org/welcome   
20 http://dicom.nema.org/   
21 http://www.ncbi.nlm.nih.gov/pubmed/22255626   
Simulation protocols and clinical workflows 
With modelling standards now in place, the focus for the VPH/Physiome community is 305 
increasingly shifting to better mechanisms, based on these standards, for comparing models 
with each other and with experimental data – a process called functional curation. In 
particular there is a need to define standards around the implementation of experimental 
protocols. One such effort, for cardiac electrophysiological models, is the Oxford ‘web lab’ 
facility22 (19). This allows the user to compare dozens of cardiac electrophysiology models 310 
under a wide variety of conditions, such as stimulating at different pacing rates, blocking 
particular ion channels with specific drugs, and generating phenotypic outputs such as s1-s2 
restitution curves for all models under test. To standardize the way CellML or SBML models 
are run and compared with experimental data, a standard called SED-ML 23  has been 
developed by the VPH/Physiome and Systems Biology communities. The SED-ML API has 315 
been incorporated into OpenCOR so that the simulation parameters can be read in from a file 
or defined in OpenCOR and exported to a SED-ML file. A tutorial on the use of CellML, 
OpenCOR and PMR is available on the VPH-Institute website24.  
Another VPH initiative that facilitates the development of computational models for the clinic 
is VPH-Share25. This major project, led by the University of Sheffield, has created a cloud-320 
based IT infrastructure and universal clinical workflow development system capable of 
supporting the construction and operation of complete software systems to extract novel and 
possibly complex biomarkers from raw clinical information, and so to provide clinicians with 
decision support for diagnosis, stratification, therapy selection and treatment planning (20). 
VPH-Share provides a completely secure environment in which researchers and clinicians can 325 
quickly assemble application components – often already available within the system - into 
fully-operational end-to-end processing chains that can, where necessary, feature significantly 
complex operations including, for example, finite element models executed on remote HPC 
machines, programmed automatically to carry out parametric sweeps and physiological 
envelope explorations. Soon to be available as a supported public service for clinical 330 
researchers, where the use of anonymised data is the norm, VPH-Share includes features 
permitting users – if they wish - to share selected elements of their work with other named 
users of the system, again using fully secure mechanisms. Also available is a stand-alone 
version of VPH-Share for individual or collaborative use within specific communities such as 
industrial and healthcare organisations, where data sensitivities or local regulations require 335 
detached operation. 
To bring the benefits of mechanistic models into the clinic requires that the semantic 
annotations mentioned above are mapped into the data storage formats used in an electronic 
health record (EHR). This concept is being tested with the Archetype data structure in 
openEHR26 (21).  340 
 
4. THE TARGETS 
The term “Virtual Physiological Human” is rarely used as a scientific definition in research 
papers.  To date in PubMed there are only 53 papers with this term, and most of them are 
                                                
22 https://chaste.cs.ox.ac.uk/FunctionalCuration    
23 http://sed-ml.org/   
24 http://www.vph-institute.org/upload/opencor-tutorial-v17_55e999c508b8a.pdf   
25 http://www.vph-share.eu/   
26 http://www.openehr.org/   
policy-oriented papers, rather than original articles; also “multiscale model” returns only 260 345 
papers, mostly in the last five years. But if we search (patient-specific[All Fields] OR subject-
specific[All Fields] OR (personalised model[All Fields] OR (personalised model[All Fields])) 
we find 2,203 papers, with a sharp increase starting from 2005 (figure 2). 
  
Figure 2.  Number of papers in PubMed on subject-specific models (left) and multiscale models (right), divided 350 
by the total number of papers indexed by PubMed in the same year. 
The VPH approach requires being able to describe pathophysiological processes in 
quantitative terms over space and time, and across vast space-time scales. So it should not 
come as a surprise that some of the most popular clinical targets for VPH models are the 
organ systems that have the best biophysical characterisation: the cardiovascular and 355 
respiratory system, and the neuromotor and musculoskeletal system. 
The mammalian heart was one of the first targets of VPH researchers.  As the VPH vision 
developed from the early work on the Cardiome Project (22-24), researchers focused more of 
specific clinical targets, such as the better planning of cardiac re-synchronisation therapy (25; 
26), the stratification toward treatment of coronary stenosis patients (27; 28), or the patient-360 
specific planning of the new transcatheter valve implantation procedures (29; 30).  
To the authors’ knowledge the first VPH technology to achieve FDA approval belongs to a 
special group where the quantity to be predicted can indeed be measured directly, but through 
a costly, invasive, and/or dangerous procedure.  Fractional Flow Reserve (FFR) expresses the 
pressure drop across coronary stenoses; it is measured with an instrumented endovascular 365 
catheter that must be passed through the stenosis.  While it has been proved that Fractional 
Flow Reserve has an accuracy > 90% in identifying if the stenosis is causing cardiac ischemia 
(31), this procedure is rarely used because of the cost, complexity, and risk that the direct 
measurement of the FFR involves.  Using a patient-specific model generated from coronary 
computed tomographic angiography images, the HeartFlow service can predict the value of 370 
the FFR without any invasive procedure (32). The HeartFlow technology has received 
recently full FDA approval, and in now available for use worldwide.  The Insigneo institute in 
Sheffield (UK) has completed a phase I clinical trial on a similar solution that uses rotational 
coronary angiography, which is far more accessible than CT angiography, especially in 
Europe (28). A similar application, which also just completed the phase I trial, makes it 375 
possible to perform an accurate differential diagnosis of pulmonary hypertension without the 
need for a delicate invasive right heart catheterisation, which is the current standard of care 
(33).  
Complex cardiac surgery, such as transcatheter aortic valve implantation (TAVI), or 
paediatric percutaneous pulmonary valve implantation, require accurate planning in order to 380 
be successful.  A new generation of VPH technologies facilitates patient-specific simulation 
of the device deployment in order to predict how it will perform if deployed in that way in 
that patient. See, for example, recent work on a particularly difficult paediatric case, at the 
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Great Ormond Street Hospital for Children in London (30). A Dutch start-up, FEOPS27, is 
testing a software technology called TAVIGuide, to assist with the planning of TAVI 385 
procedures. 
The accidental finding of asymptomatic aneurysms poses a significant challenge to the 
clinical specialist who must decide whether to treat it, which usually involves some serious 
risks, or leaves the aneurysm untreated, with the risk that the lesion keeps growing and 
eventually bursts, producing a massive haemorrhage. So predicting the risk of rupture of 390 
individual aneurysms remains one of the holy grails for VPH research.  But the problem is 
very complex, and all technologies are in early stages of development.  Some interesting 
results were obtained for abdominal aortic aneurysms (34), while for cerebral aneurysms a lot 
more research is required (35). 
For the musculoskeletal system one of the first clinical problems VPH technologies 395 
confronted is the risk of bone fracture in osteoporotic patients (36) (37) (38). Today, the 
Insigneo predictive technology can correctly discriminate in retrospective studies fractured 
and non-fractured patients with an accuracy of 75%-84%, depending on the age distribution 
of the patients (39) (40). An interesting derivation of this research line is the stochastic 
modelling of neuromuscular control, which has allowed to consider sub-optimal muscle 400 
activation patterns (41; 42), enabling population modelling of the risk of hip fracture (38), but 
more recently showed to improve the predictive accuracy of musculoskeletal dynamics 
models even in relation to normal health subjects (43).  Whole body musculoskeletal patient-
specific models are also used in the treatment planning and functional grading of paediatric 
cerebral palsy patients (44); Fregly, 2009 #460; Oberhofer, 2010 #461; Ravera, 2010 #462; 405 
Scheys, 2011 #463; Scheys, 2011 #464; Bosmans, 2014 #465; Riccio, 2015 #466]. 
Multiscale approaches were used to investigate more fundamental problems around the role 
that molecular constituents and their spatial organisation plays in the macroscopic mechanical 
properties of bone (45) (36) (46) (47) (48), tendons (49-53), skeletal muscles (50; 54-57), and 
cartilage (58-61) and ligaments.   410 
A very important feature of all connective tissues is their ability to adapt to altered 
environmental requirements (62) (63) (64) (65) (66), and to repair damage (67) (68); both 
topics have been thoroughly investigated using VPH approaches.  In relation to bone 
remodelling, some authors focused their attention on the multiscale interaction between solid 
and fluid phases (69), which is suspected to play a role in bone tissue adaptation.  415 
VPH approaches were used to investigate the complex mechanobiology of articular cartilage 
(60), the ethiopathogenesis of osteoarthritis (58), the mechanisms that drive the formation of 
focal subchondral lesions in rheumatoid arthritis (59), and the ethiopathogenesis of 
osteoarthritis in relation to muscle weakening (70). Rare diseases such as osteogenesis 
imperfecta were also targets of VPH modelling studies (71). 420 
In dental research VPH modelling has been used to determine the mechanical stresses induced 
in the alveolar region during mastication (72), and in relation to the aseptic loosening of 
dental implants (73). Uterine biomechanics, and the role of pelvic musculature during 
parturition, have also been investigated (74; 75). Another interesting target is oncology, for 
example predicting the response for individual patients with breast cancer undergoing neo-425 
adjuvant therapy (76). 
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5. TWO CASE MULTISCALE MODELLING STUDIES 
In this section we describe two VPH/Physiome physiological modelling projects that build on 
the multiscale modelling methodology described in Section 3 and have reached some level of 430 
clinical relevance. There are many other clinically relevant examples involving other organ 
systems, but these two are chosen as exemplifying two of the first VPH/Physiome projects to 
address multiscale issues. In most cases clinically oriented projects deal primarily with only 
one or two spatial scales, but many are on a path to link clinically relevant tissue/organ level 
models, usually derived from clinical imaging, with molecular and cellular mechanisms. Most 435 
are also capable of being applied in a patient-specific way – using multiscale physiological 
measurements from the clinic to guide diagnostic analysis and therapeutic procedures. 
The two examples we give here all involve international collaborations with VPH connections 
and funding. They are: (i) a cardiac electrophysiology modelling project for the diagnosis of 
cardiac arrhythmias, and (ii) a project on modelling respiratory biomechanics for the 440 
diagnosis and treatment of COPD and asthma. 
 (i) Cardiac electro-mechanics modelling: Diagnosis of cardiac arrhythmias 
Models of cardiac ion channels by Denis Noble were among the first molecular level models 
developed in computational physiology (15), following the Noble-prize winning squid axon 
studies of Hodgkin and Huxley (77). Continuum mechanics models of the heart with 445 
anatomically realistic geometry and structure were developed later (22; 78; 79). These were 
soon coupled also with myocardial wave propagation to produce multiscale cardiac electro-
mechanics models (80) and subsequently with ventricular flow and coronary flow models 
(81). This is the work that initiated the IUPS Physiome Project in 1997 and, as mentioned 
earlier, led to the proposal for a VPH project and subsequent investment in computational 450 
physiology by the European Commission. All four chambers of the heart are now represented 
in many of these models which are now used in many clinically focussed studies, including 
the treatment of arrhythmias (82), coronary disease (83), mitral and aortic valve failure (84) 
and both diastolic and systolic heart failure (85). We give one such example here, on the 
diagnosis of a cardiac arrhythmia, as an illustration of the need to deal with the variability of 455 
gene expression in a human population as well as the complexity of having multiple ion 
channels, their intracellular trafficking and their spatial distribution in tissue, contributing to 
the clinically observed phenotype at the whole heart level. 
The cardiac action potential is generated by the flow of ions across cardiac cell membranes. 
The rapid upstroke is associated with a huge (rapidly self-terminated) influx of sodium ions 460 
that is responsible for the QRS complex of the EKG (Figure 1). The long (≈100ms) plateau, 
needed to allow time for muscle contraction before the next heart beat, is maintained by 
several inward ion fluxes, including the entry of the calcium ions that trigger the release of 
internal calcium stores to activate the contractile proteins. In most electrically active cells the 
resting membrane potential is maintained by an open potassium channel (with high 465 
intracellular K+ and a Nernst potential of -85mV) that briefly conducts a positive outward 
current when the voltage raises towards the +35mV Nernst potential of the now open Na+ 
channel. Because the cardiac cell has to maintain its depolarised (positive membrane 
potential) state for the period of the plateau, it cannot afford to have a prolonged outward flow 
of potassium ions (since these ions would have to be pumped into the cell again at high 470 
metabolic cost) and has evolved an ‘inwardly rectifying’ potassium channel called IK1, as 
illustrated in Figure 1. Two other types of potassium channel, IKr (r for ‘rapid’) and IKs (s for 
‘slow’), have therefore evolved to repolarise the cell towards its resting membrane potential 
(where IK1 can take over). 
Repolarisation at the cell level is reflected by the ‘T-wave’ at the body surface on the EKG 475 
(see Figure 3) and the time from the peak inward sodium current (the ‘Q-wave’ on the EKG) 
to the peak of the T- wave is the clinically observed ‘QT interval’. Any mutation that reduces 
the density of IKr or IKs channels or detrimentally alters the channel kinetics leads to delayed 
repolarisation and a longer than normal QT interval - called LQTS (‘long QT syndrome’). 
This is particularly dangerous since reactivation of an inward sodium or calcium current 480 
during the plateau can generate a wave of electrical depolarisation spiralling around the heart 
(an ‘arrhythmia’ referred to as ‘torsade de pointes’ because of the apparently random dancing 
pattern on the EKG) that can quickly break up into multiple spirals ‘ventricular fibrillation’ 
that render the myocardium as an uncoordinated quivering mass not able to pump blood (a 
‘heart attack’). 485 
Repolarising currents that produce the T-wave include IKs and IK1 as well as IKr. One 
particular inherited LQTS condition called LQTS2 (resulting from mutations of the KCNH2 
gene of the IKr channel) manifests as both an LQT interval on the EKG and a splitting of the 
T-wave - called a ‘bifid’ or notched T-wave. Most (>90%) of the missense mutations of 
KCNH2 exert their effect through reduced trafficking of the protein from the nucleus to the 490 
cell membrane and hence reduced conductance of the IKr channel. More pronounced notching 
appears to be associated with more severe forms of LQTS2 and it would therefore be 
clinically useful to understand how the notching arises since different drugs are needed to 
treat different underlying causes for particular patients. 
Multiscale modelling of arrhythmogenic conditions such as LQTS, to improve the precision 495 
of clinical diagnosis and therefore treatment strategies, requires anatomically based models 
that capture the fibrous-sheet architecture of the myocardium, the spatial distributions of ion 
channel densities and detailed kinetics of all the relevant ion channels. This is illustrated in 
Figure 3 for LQTS2.  
 500 
Figure 3. Anatomically based organ level models of the heart and torso include the fibrous-sheet architecture of 
the heart and the spatial distribution of ion channels (top left). The normal cellular action potential (top right) is 
repolarised by several potassium channel currents (IKr, IKs and IK1). Mutations in IKr cause LQTS2 (long QT 
syndrome type 2) that delays repolarisation and can be associated with a notched T wave. Modelling by Sadrieh 
et al (82) shows that the two peaks seen in LQTS2 (shown here in green) are associated with different 505 
myocardial cell populations, preferentially expressing IKr and IK1, respectively. 
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A study by Sadrieh et al (82) showed that the notched T-wave in LQTS2 is associated with 
two populations of cells, one with greater expression of IKr, generating the first peak of the 
notched T-wave, and one with greater expression of IK1, generating the second peak of the 510 
notched T-wave. The dip between these two peaks (corresponding to an inward current) 
appears to be associated with reactivation of sodium current. The diagnosis of LQTS2 is 
complicated by the variability of T-wave shape.  
Readers interested in the details of how this model is used clinically should consult (82). We 
have briefly described it here because it very nicely illustrates a clinical application of cardiac 515 
modelling that builds on the VPH foundations.  
 (ii) Respiratory modelling: The diagnosis and treatment of COPD and Asthma 
Anatomically based finite element models of the airways and vasculature of the lungs have 
also been under development for some time (86). A structure-based airway model, for 
example when coupled with a model of airway resistance and tissue elasticity (87) can predict 520 
the distribution of ventilation (V) throughout the lungs (see Figure 4a). Similarly, a vascular 
model coupled with capillary recruitment and the effects of hydrostatic pressure, predicts the 
distribution of perfusion (Q) throughout the lungs (88) (Figure 4b). Computing the ratio of 
ventilation to perfusion (V/Q) for a region of tissue and coupling this to a model of the 
biophysics of oxygen exchange (89), yields the arterial and venous blood gases throughout 525 
the lungs (Figure 4c). These models are used to develop a treatment strategy for patients with 
by fitting the vessel structure to clinical CT images and using the observed 3D distribution of 
emboli imposed on the model. 
 
 530 
Figure 4. (a) A structure-based airway model coupled with a model of airway resistance and tissue elasticity 
predicts the distribution of ventilation (V), shown here as a vertical distribution; (b) a vascular model, coupled 
with capillary recruitment and the effects of hydrostatic pressure, predicts the distribution of perfusion (Q); (c) 
Left: the ratio of ventilation to perfusion (V/Q) for a region of tissue. Coupling this with a model of the 
biophysics of oxygen exchange yields the spatial distribution of arterial and venous blood gases throughout the 535 
lungs. 
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
!
Lu
n
g
 h
ei
gh
t 
(%
) 
100 
75 
50 
25 
0 
V,!Q,!or!V/Q 
V 
100 
75 
50 
25 
0 
!
Lu
n
g
 h
ei
gh
t 
(%
) 
V,!Q,!or!V/Q 
Q 
(a)$
(b)$
(c)$
80 
140 mmHg 
!
Lu
n
g
 h
ei
gh
t 
(%
) 
V,!Q,!or!V/Q 
!! V 
Q 
V/Q 
10
0 
75 
50 
25 
0 
For further examples of the clinical application of these models, see (90-93). 
 
6. THE REMAINING CHALLENGES 
(i) The Physiome Project 540 
The main task facing the nascent Physiome Project committee when it was formed in 1997 
was to establish standards for encoding models and data such that physiological models could 
be demonstrably reproducible and reusable. The model encoding standards also needed to 
support modularity – since complex multiscale models must be built from independently 
validated modular components often developed by many different research groups. These 545 
standards ensure that the models can be curated (i.e. that they work, have consistent units and 
obey the laws of physics where appropriate) and are modular and annotated with bio-
ontologies (to ensure reusability).  
These standards and their associated modelling infrastructure have largely been completed. 
The challenge now is two-fold: (i) incentives are needed to persuade modellers to use the 550 
standards in order to ensure that their models are reusable by others, and (ii) a framework is 
needed to ensure that the multiscale models developed by independent research groups can be 
connected into integrative models of whole body physiology for application to healthcare – 
not least because the epidemic of chronic diseases that confronts the developed world can 
only be addressed by methods that deal with highly complex physiological processes 555 
involving multiple organs and tissue types but always linked down to molecular mechanisms.   
To address these two related challenges, we propose two new developments. One is to 
establish a new journal, the Physiome Journal, and the other is to create a new web portal, 
based on models from the journal, that provides access to integrative whole body physiome 
models.  560 
The journal should solicit papers that describe models and associated data encoded in 
physiome standards. It should complement journals that describe physiological experiments 
and the use of models to interpret these experiments. The prospect of citable articles that fully 
document a model for the benefit of others in a (hopefully) high impact journal should 
provide the incentive for modellers to make the effort to ensure that their models are curated, 565 
annotated and modular – since they will then be getting a second citable paper to complement 
the one submitted to the existing journals. Some of the essential and desirable aspects of the 
new journal are that it is open access (essential) and that where possible it publishes ‘smart’ 
papers such that readers can run the models and see results immediately, including the ability 
to change parameters and observe the consequences.   570 
It is important that the Physiome Journal is not seen to be in competition with existing 
journals, but rather that the new journal establishes a relationship with these journals such that 
the two papers (one focussed on experimental data and model interpretation, the other on 
model sharing) can be submitted at the same time, the first to a physiology, bioengineering or 
biophysics journal and the second to the Physiome Journal. Ideally the curated and annotated 575 
model(s) associated with a pair of papers would be available for download from the Physiome 
Journal website at the same time as the experimental paper is published. The Physiome 
Journal should also publish papers that provide a comparative review of models in an area of 
physiology.       
The second proposal for a web portal is being developed by the VPH-Institute such that 580 
models published by the Physiome Journal would be automatically linked into the evolving 
whole body physiological models, including whole body circulation models, physiologically 
based pharmacokinetic (PBPK) and pharmacokinetic-pharmacodynamic (PKPD) models, 
available on the VPH portal. One role for the portal will be to identify areas where there are 
no models and to encourage new experimental and modelling efforts to fill those gaps. 585 
 
 (ii) VPH Project 
The types of challenges that still remain open for the VPH vary considerably depending on 
the specific application and on the Technology Readiness Level (TRL) of the technology at 
hand. A possible definition of the TRLs in this context is the following: 590 
 
Technology Readiness Level Description of RTD activities 
TRL1: Technical Watch Monitor fundamental technological innovations; monitor discovery of fundamental biological mechanisms. 
TRL2: Basic Technology Research Apply fundamental technological innovation to the quantification, prediction, and modification of fundamental biological mechanisms. 
TRL3: Research to Prove Feasibility Hypothesis testing and initial proof of concept (PoC) is demonstrated in a limited number of in silico & in vitro models. 
TRL4: Technology Demonstration Proof of concept and safety are demonstrated in a defined laboratory or animal model. 
TRL5: Technology Demonstration Pre-clinical studies, including GLP animal safety & toxicity, sufficient to support industrial application. 
TRL6: Technology Demonstration Phase 1 clinical trials: support to proceed to phase 2 clinical trials; safety, usability, impact, accuracy on small cohort. 
TRL7: System/Subsystem Development Phase 2 clinical trials: accuracy and efficacy on medium cohort; scalability and impact 
TRL8: System Test, Launch, & Operations Phase 3 clinical trials: efficacy on large cohort. Cost-benefit analysis, primary research for Health Technology Assessment. 
TRL9: Post marketing studies and surveillance Post marketing studies and surveillance; registers, failure analysis, post-mortem examinations. 
For those technologies that have completed TRL7 or higher (vFFR, osteoporosis, abdominal 
aneurysms) most of the challenges are in the re-engineering of the process to handle large 
volume at low costs, i.e. a need for higher degree of automation.  A lot of patient-specific 
models require massive manual pre- and post-processing done by a highly qualified operator; 595 
while this is acceptable during the development phase, large scale deployment, especially 
under tight cost-benefit targets, require a massive re-engineering of the technologies. 
A second problem for mature applications is the turn-around time.  Today most VPH 
applications work like a laboratory test, the patient comes in today, and the doctor will receive 
the results in 1-4 days; however, in many clinical applications, the ideal time-frame is that of 600 
a clinical consultation, typically 15-45 minutes: the patient comes in, the nurse collects all the 
data and requests the VPH simulation, so that when the specialist visits the patient a few 
minutes later, the prediction is already available to support the clinical decision.  The extreme 
case is when the VPH model is integrated in a real-time application, such as pre-operative 
planning (94). In many cases the turn-around time is dominated by the pre- and post-605 
processing, so the issues falls back to the need for re-engineering the processing workflow; 
but in many others the computational complexity is the limiting issue.  Here research goes in 
many different directions from pre-computed solutions, parallelisation or other hardware 
related optimisations (such as for example GPU porting), but also the development of 
reduced-order models that provide the results at a fraction of the computational cost in 610 
exchange for a small reduction of the predictive accuracy, small enough to remain clinically 
useful. 
For technologies that have achieved a TRL5, the biggest challenge is clinical credibility.  
Here what is necessary is clinical research, where the new VPH-based clinical pathway is 
compared in term of accuracy and/or efficacy to the current standard of care, in order to 615 
demonstrate that the increased complexity that a VPH-based pathway usually involves is fully 
justified by the massive benefits it yields. 
For applications with lower RTL, the main challenge is to bridge the large volume of work 
that is being done around the biochemical modelling of molecular pathways in a single cell 
(what is normally referred as molecular system biology) to the biophysics modelling at tissue, 620 
organ and organism scales.  There are operational challenges (for example bridging the cell-
tissue scale is particularly difficult), but also cultural issues, as this scale transition marks the 
passage from physiologists, biophysicists and bioengineers to pharmacologists, biologists, 
and geneticists.  
 625 
7. CONCLUSIONS 
Charles Taylor, the principal investigator behind the HeartFlow CT-vFFR technology, 
published his first paper on this topic in 1999 (95).  The development of the sugar metabolism 
model now used in the FDA-approved Cobelli-Kovatchev pre-clinical simulator (96) started 
in 1979 (97).  The Oxford Virtual Assay for in silico cardio-toxicity is based on the work of 630 
Denis Noble that started in the ‘60s (15). While developing and validating VPH models today 
is probably easier than it was for these pioneers, and it will get easier in the future, it is clear 
that the development of a subject-specific multiscale predictive model fully validated for 
clinical use requires a considerable investment of time and money.  But the potential payback 
is huge: an FFR procedure cost $3000-$5000 USD, and can be performed only in specialised 635 
centres; a vFFR cost considerably less, and almost every hospital with a CT system and 
access to the HeartFlow service can perform it.  But much more important, with a vFFR 
model that support virtual stenting, the cardiologist can play “what-if”, and deal much more 
effectively with patients with multiple stenoses, traditionally difficult to plan. 
But these are the low-hanging fruit.  In the long-term VPH models enable Predictive 640 
Medicine, where the clinical specialist can make critical decisions based on reliable, patient-
specific predictions, with significant improvements in the efficacy of care. Reliable 
predictions of clinically relevant disease manifestations make finally possible a Personalised 
Medicine, currently burdened by unrealistic expectations of molecular biology technologies.  
Personalised predictions are the precondition for the expansion of Preventive Medicine; only 645 
accurate predictions ahead of time can truly enable a personalised prevention.  Last, but not 
least, we believe predictive technologies can play a role also in enabling a more Participative 
Medicine.  A typical example is geriatric oncology, a clinical domain frequently at risk of 
therapeutic obstinacy; a much more reliable ability to predict the prognosis as a function of 
the treatment options that are available, would make recommendations of palliative therapy 650 
much easier than the current prognostic uncertainty allows. 
The first ten years of VPH research have shown the enormous potential of this approach; now 
it is time for massive research investment in this area, to deliver in full the promise of 
predictive medicine. 
 655 
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